RARA CRAFT DATABASE for FDA Medical Devices
PMAP190028S009

FDA DEVICE FACTS

cobas HPV

Roche Molecular Systems, Inc.

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEMay 14, 2024PRODUCT CODEMAQ

Indications for use

cobas HPV for use on the cobas 5800/6800/8800 Systems (cobas HPV) is a qualitative in vitro test for the detection of high-risk Human Papillomavirus. This test detects the high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 in the specimens listed below. Clinician-collected cervical specimens should be obtained using an endocervical brush/spatula or broom and placed in the ThinPrep Pap Test PreservCyt Solution. Self-collected vaginal specimens, obtained in a healthcare setting, can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained. cobas HPV is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of individuals with a cervix to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026